Background: Egypt has the highest prevalence of HCV worldwide 13.8 % .The classic effective treatment is Interferon alpha (IFN-α) in combination withribavirin . As these therapies have side effects and high costs, it is importantto identify patients having the best chance to respond before initiation oftherapy. The monitoring of rapid virological response (RVR) is therefore animportant tool for quick identifying non-responders, permitting therapydiscontinuation and avoiding adverse effects and costs.Objective: The objective of the study is to determine a simple and easy test thatcan be applied to predict RVR. The aim of the study is to find a correlationbetween the lipid profile of the patient before starting treatment and the RVR.Methods: This study included 56 non-cirrhotic, non-diabetic, non-hypertensive,non-ischemic HCV positive patients. Their lipid profile prior to treatment will beassessed. Patients were then divided into 2 groups, group I with 27 patients withnormal lipid profile and group II with 29 patients with high lipid profile. Datawill be statistically analyzed in order to study the correlation between lipidprofile and RVR.Results: pretreatment cholesterol and LDL were significantly associated withRVR.RVR in group II was 62.9%, while it was only 22.2% in group I, with a p value of<0.01.Conclusion: Our data suggest that pretreatment cholesterol and LDL is stronglyassociated with RVR. Assessing the lipid profile in all chronic HCV patients atbaseline would be a useful tool in predicting RVR.